Research programme: phosphodiesterase IV inhibitors - ZambonAlternative Names: PDE4 inhibitors research programme - Zambon; Phosphodiesterase IV inhibitors research programme - Zambon; Research programme: PDE4 inhibitors - Zambon
Latest Information Update: 16 Sep 2005
At a glance
- Originator Zambon Group SpA
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 29 Jul 2004 Preclinical trials in Chronic obstructive pulmonary disease in Europe (PO)